Loading…
Employees: 1,115
Size Chongqing Lummy Pharmaceutical (300006.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.55B, the 1591st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.76 on 6 Nov 2026.
Performance Over six months the shares gained 52.7%, against -4.0% for the median peer and -16.4% for the China market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 6.2% over the last twelve months (peer median +6.2%); the operating margin is -18.6% (peer median 10.2%).
Valuation It trades at 13.6× enterprise value to sales against a peer median of 3.5× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +63 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 12.1 points below its cost of capital (6.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥720M | CN¥769M | CN¥785M | CN¥883M | CN¥874M |
| Revenue growth | — | -2% | -11% | +1% | — |
| Gross profit | CN¥394M | CN¥389M | CN¥466M | CN¥569M | CN¥593M |
| EBITDA | n/a | -CN¥47.7M | -CN¥66.9M | -CN¥32.8M | -CN¥72.5M |
| Net income | -CN¥119M | -CN¥135M | -CN¥87.8M | -CN¥8.93M | -CN¥68.7M |
| Free cash flow | CN¥40.4M | CN¥23.2M | CN¥146M | -CN¥46.9M | CN¥50.0M |
| Capital expenditure | CN¥30.6M | CN¥38.2M | CN¥75.5M | CN¥59.3M | CN¥68.2M |
| Total debt | CN¥358M | CN¥379M | CN¥495M | CN¥274M | CN¥365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300006.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +81.8% | +1.6% | highest of 21 |
| 6-month return | +52.7% | -4.0% | 3rd highest of 21 |
| Distance from 52-week high | -13.0% | -19.8% | 5th highest of 21 |
| Revenue growth (TTM) | -6.2% | +6.2% | 5th lowest of 19 |
| Operating margin | -18.6% | 10.2% | 6th lowest of 19 |
| EV / Sales | 13.6× | 3.5× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 49.9% | 5.4% | most demanding of 11 |
| Growth delivered (Del g) | -13.2% | +12.3% | lowest of 11 |
| Hurdle (Req g minus delivered) | +63.1 pp | -6.0 pp | most demanding of 11 |
| ROIC minus cost of capital | -12.1 pp | +1.2 pp | 5th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 1.5× | -5.8% | +1.9% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |